HSOL [Hanwha Q CELLS] 424B2:
[]
TPI [TIANYIN PHARMACEUTICAL] 10-Q: FORM 10-Q (Mark One) For the quarterly period
[FORM 10-Q (Mark One) For the quarterly period ended September 30, 2010 For the transition period from _______________ to _______________ Tianyin Pharmaceutical Co., Inc. Delaware (State or other jurisdiction of incorporation or organization) 23rd Floor, Unionsun Yangkuo Plaza No. 2, Block 3, Renmin Road South Chengdu, P. R. China, 610041 +0086-028-86154737 (Address, including zip code, and telephone number, Large Accelerated] [CERTIFICATION OF CHIEF EXECUTIVE OFFICER I, Guoqing Jiang certify that: 1. I have reviewed this quarterly report on Form 10-Q of Tianyin Pharmaceutical Co., Inc. 2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the] [CERTIFICATION OF CHIEF FINANCIAL OFFICER I, James Jiayuan Tong, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Tianyin Pharmaceutical Co., Inc. 2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2)T he information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Guoqing Jiang Chief Executive Officer & Chairman EX-32.1 4 ex32one.htm CERTIFICATION] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. James Jiayuan Tong Chief Financial Officer, Chief Accounting Officer, Chief Business and Development Officer, Director EX-32.2 5]
LEDS [SemiLEDs] CORRESP: (Original Filing)
[ORRICK, HERRINGTON & SUTCLIFFE 43RD FLOOR, GLOUCESTER TOWER THE LANDMARK 15 QUEENS ROAD CENTRAL HONG KONG tel 852-2218-9100 fax 852-2218-9200 WWW.ORRICK.COM November 12 , 2010 VIA EDGAR AND HAND DELIVERY Division of Corporate Finance 100 F Street, N.E. Mail Stop Number 3030 Attn: Russell Mancuso, Branch Chief, Legal Gabriel Eckstein Daniel Morris, Special Counsel Martin James Kevin Vaughn, Branch Chief,]
BSPM [Biostar Pharmaceuticals,] 10-Q: FORM 10-Q (Mark One) x September 30, 2010
[FORM 10-Q (Mark One) x September 30, 2010 For the quarterly period ended: Or For the transition period from ______________ to _______________ 001-34708 BIOSTAR PHARMACEUTICALS, Maryland 20-8747899 (State or other jurisdiction oforporation of origination) (I.R.S. Employer Identification Number) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province Peoples Republic of China] [CERTIFICATION I, Ronghua Wang, certify that: 1. I have reviewed this quarterly 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with] [CERTIFICATION I, Deyin Chen, certify that: 1. I have reviewed this quarterly 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with] [CERTIFICATION (1) (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany at thetes and for the periods indicated. ex32-1.htm 4 EX-32.1] [CERTIFICATION (1) (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany at thetes and for the periods indicated. ex32-2.htm 5 EX-32.2]
KGJI [KINGOLD JEWELRY] 8-K: (Original Filing)
[Earnings/News Release Kingold Jewelry Reports Third-Quarter Results Revenue of $169.7 Million 81.1% Higher Year over Year Net Income of $5.2 Million 135.1% Higher Year over Year KGJI WUHAN CITY, China, November 12, 2010 (GLOBE NEWSWIRE) -- Kingold Jewelry, Inc. (NASDAQ: Net sales increased 81.1% to $169.7 million for the three months ended September 30, 2010, compared to $93.7 million for] [Item 2.02 Results of Operations and Financial Condition. On Novemb er 12, 2010, Kingold Jewelry, Inc. ("Kingold") issued a press release regarding Kingold ’ (d)]
TPI [TIANYIN PHARMACEUTICAL] SC 13D/A: (Original Filing)
[FORM OF RULE 10B5-1 TRADING PLAN October 11, 2010 This Trading Plan (the “Trading Plan”) is entered into on Time Poly Management Limited Tianyin Pharmaceutical Co., Inc. TPI between Seller and UBSFS agree as follows: 1. Specific Plan of Sale 2. Fees/Commissions 0.05 3. (a) (b) All investment decisions on behalf of Seller, including without limitation, decisions to purchase or] [(Amendment No. 3) TIANYIN PHARMACEUTICAL CO., INC. (Name of Issuer) SCHEDULE 13D/A Common Stock, $.001 par value (Title of Class of Securities) 88630M104 (CUSIP Number) Time Poly Management Ltd. Unit 06, 21/F, Beautiful Group Tower, 77 Connaught Road, Central, Hong Kong Telephone: (852) 3583 3340; Fax: (852) 3585 6021 (Name, Address and Telephone Number of Person Authorized to Receive Notices]
LEDS [SemiLEDs] CORRESP: ORRICK, HERRINGTON & SUTCLIFFE 43RD FLOOR, GLOUCESTER TOWER
[ORRICK, HERRINGTON & SUTCLIFFE 43RD FLOOR, GLOUCESTER TOWER THE LANDMARK 15 QUEENS ROAD CENTRAL HONG KONG tel 852-2218-9100 fax 852-2218-9200 WWW.ORRICK.COM November 12 , 2010 VIA EDGAR AND HAND DELIVERY Division of Corporate Finance 100 F Street, N.E. Mail Stop Number 3030 Attn: Russell Mancuso, Branch Chief, Legal Gabriel Eckstein Daniel Morris, Special Counsel Martin James Kevin Vaughn, Branch Chief,]
CPHI [CHINA PHARMAS,] DEFA14A: (Original Filing)
[SCHEDULE 14A INFORMATION o Check the appropriate box: o Preliminary Proxy Statement o 6(e)(2) ) o Definitive Proxy Statement Definitiveditional Materials o CHINA PHARMAS, Payment of Filing Fee (Check the appropriate box): No fee required. o Feemputed on table below per Exchange Act Rules14a-6(i)(1) and 0-11. (1)]
GSOL [GLOBAL SOURCES] 6-K: (Original Filing)
[YEAR 2010 / 3 rd QUARTER The following discussion of our financial condition and results of operations should be read in conjunction with the accompanying financial statements. Overview We are a leading business-to-business (B2B) media company and a primary facilitator of two-way trade with Greater China. The core business is facilitating trade from Greater China to the world, using a] [GLOBAL SOURCES LTD. AND SUBSIDIARIES At At September 30 December 31 2010 2009 (Unaudited) ASSETS Current Assets: Cash and cash equivalents $ 85,292 $ 91,553 Term deposits with banks 1,467 60,357 Available-for-sale securities 6,763 6,423 Accounts receivable, net 4,646 3,438 Receivables from sales representatives 6,511 5,607 Inventory 425 600]
KGJI [KINGOLD JEWELRY] 8-K: Earnings/News Release Kingold Jewelry Reports Third-Quarter Results Revenue
[Earnings/News Release Kingold Jewelry Reports Third-Quarter Results Revenue of $169.7 Million 81.1% Higher Year over Year Net Income of $5.2 Million 135.1% Higher Year over Year KGJI WUHAN CITY, China, November 12, 2010 (GLOBE NEWSWIRE) -- Kingold Jewelry, Inc. (NASDAQ: Net sales increased 81.1% to $169.7 million for the three months ended September 30, 2010, compared to $93.7 million for] [Item 2.02 Results of Operations and Financial Condition. On Novemb er 12, 2010, Kingold Jewelry, Inc. ("Kingold") issued a press release regarding Kingold ’ (d)]
